Traders Sell Shares of Pfizer, Inc. (PFE) on Strength (PFE)

Traders sold shares of Pfizer, Inc. (NYSE:PFE) on strength during trading hours on Thursday. $52.01 million flowed into the stock on the tick-up and $105.65 million flowed out of the stock on the tick-down, for a money net flow of $53.64 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.18 for the day and closed at $35.20

Several analysts have issued reports on PFE shares. Berenberg Bank restated a “hold” rating and issued a $36.00 target price (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. UBS AG set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $38.48.

The company has a debt-to-equity ratio of 0.58, a current ratio of 1.34 and a quick ratio of 1.06. The company has a market cap of $209,816.89, a PE ratio of 14.08, a P/E/G ratio of 2.49 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the business earned $0.61 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. sell-side analysts anticipate that Pfizer, Inc. will post 2.59 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.64%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of PFE. Janus Henderson Group PLC boosted its holdings in shares of Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Pfizer in the 2nd quarter worth about $268,389,000. Canada Pension Plan Investment Board boosted its holdings in shares of Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after purchasing an additional 7,649,416 shares in the last quarter. Finally, Longview Partners Guernsey LTD boosted its holdings in shares of Pfizer by 32.0% in the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after purchasing an additional 5,901,100 shares in the last quarter. Hedge funds and other institutional investors own 69.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/11/11/traders-sell-shares-of-pfizer-inc-pfe-on-strength-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply